Recent advances in the treatment of bladder cancer

References

• Jemal A, Murray T, Ward E et al. Cancer statistics. CA Cancer J. Clin. 55, 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review. Urology 61, 109–118 (2003).
   PubMed Web of Science ®Google Scholar
• Bas WG, Henk G, Theo H. Urine markers for bladder cancer surveillance: a systemic review. Eur. Urol. 47, 736–748 (2005).
   PubMedGoogle Scholar
• Dey P. Urinary markers of bladder carcinoma. Clinica Chimica. Acta. 340, 57–65 (2004).
   PubMedGoogle Scholar
• Sylvester RJ, Oosterlink W, van der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage TaT1 bladder cancer: a meta analysis of published results of randomized clinical trials. J. Urol. 171, 2186–2190 (2004).
   PubMed Web of Science ®Google Scholar
• Bohle A, Jocham D, Bock PR. Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J. Urol. 169, 90–95 (2003).
   PubMed Web of Science ®Google Scholar
• Shelley MD, Wilt TJ, Coles CB et al. Intravesical Bacillus Calmette-Guerin is superior to mitomycin C in reducing tumor recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. Br. J. Urol. Int. 93, 485–490 (2004).
   Google Scholar
• Cheng CW, Siu Foon PC, Lung WC et al. Twelve-year follow-up of a randomized prospective trial comparing Bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. Int. J. Urol. 12, 449–455 (2005).
   PubMed Web of Science ®Google Scholar
• Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur. Urol. 37, 9–15 (2000).
   PubMedGoogle Scholar
• Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168, 1964–1970 (2002).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J. Urol. 163, 1124–1129 (2000).
   PubMed Web of Science ®Google Scholar
• Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63, 682–687 (2004).
   PubMed Web of Science ®Google Scholar
• Prout G, Marshall VF. The prognosis with untreated bladder tumors. Cancer 9, 551–558 (1956).
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Nishiyama H, Tomonori H, Watanabe J et al. Clinical outcome of a large scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1,131 patients treated during 1990–2000 in Japan. Eur. Urol. 45, 176–181 (2004).
   PubMed Web of Science ®Google Scholar
• Gerharz EW, Mansson A, Mansson W. Quality of life in patients with bladder cancer. Urol. Oncol. 23, 201–207 (2005).
   PubMed Web of Science ®Google Scholar
• Leissner J, Ghoneim MA, Abol-Enein H et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J. Urol. 171, 139–144 (2004).
   PubMed Web of Science ®Google Scholar
• Poulson AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J. Urol. 160, 2015–2020 (1998).
   PubMedGoogle Scholar
• Vieweg J, Gschwend JE, Herr HW, Fair WR. The impact of primary stage on survival in patients with lymph node positive bladder cancer. J. Urol. 161, 72–76 (1999).
   PubMed Web of Science ®Google Scholar
• Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder: significance for staging and prognosis. Br. J. Urol. Int. 85, 817–823 (2000).
   Google Scholar
• Vazina A, Dugi D, Shariat SF et al. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J. Urol. 171, 1830–1834 (2004).
   PubMed Web of Science ®Google Scholar
• Brossner C, Pycha A, Toth A et al. Does extended lymphadenectomy increase the morbidity of radical cystectomy? Br. J. Urol. Int. 93, 64–66 (2004).
   Google Scholar
• Herr HW, Lee C, Chang S et al. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J. Urol. 171, 1823–1828 (2004).
   PubMed Web of Science ®Google Scholar
• Bochner BH, Cho D, Herr HW et al. Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J. Urol. 172, 1286–1290 (2004).
   PubMed Web of Science ®Google Scholar
• Abdel-Latif M, Abol-Enein H, El-Baz M et al. Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis. J. Urol. 172, 85–89 (2004).
   PubMedGoogle Scholar
• Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J. Urol. 169, 943–945 (2003).
   PubMed Web of Science ®Google Scholar
• Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: the concept of lymph node density. J. Urol. 170, 35–41 (2003).
   PubMed Web of Science ®Google Scholar
• Herr HW, Bochner BH, Dalbagni G et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J. Urol. 167, 1295–1298 (2002).
   PubMed Web of Science ®Google Scholar
• Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J. Clin. Oncol. 23, 2358–2365 (2005).
   PubMed Web of Science ®Google Scholar
• Huguet J, Crego M, Sabate S et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur. Urol. 48, 53–59 (2005).
   PubMed Web of Science ®Google Scholar
• Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet 4, 489–497 (2003).
   Google Scholar
• Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859–866 (2003).
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361, 1927–1934 (2003).
   PubMed Web of Science ®Google Scholar
• Hall RR. MRC Advanced Bladder Cancer Group. Updated results of a randomized controlled trial of neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer. Am. Soc. Clin. Oncol. Annual Meeting Summaries 54 (2002).
   Google Scholar
• Winquist E, Kirchner TS, Segal R et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol. 171, 561–569 (2004).
   PubMed Web of Science ®Google Scholar
• Sherif A, Holmberg L, Rintala E et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur. Urol. 45, 297–303 (2004).
   PubMed Web of Science ®Google Scholar
• Herr HW, Faulkner JR, Grossman HB et al. Surgical factors influence bladder cancer outcomes: a co-operative group report. J. Clin. Oncol. 22, 2781–2789 (2004).
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Petrylak DP. Perioperative chemotherapy for bladder cancer. Crit. Rev. Onc. Hem. (2005) (In Press).
   PubMedGoogle Scholar
• Ragahavan D. Chemotherapy and cystectomy for invasive transistional cell carcinoma of the bladder. Urol. Oncol. 21, 468–474 (2003).
   PubMedGoogle Scholar
• Shariat SF, Tokunaga H, Zhou J et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 22, 1014–1024 (2004).
   PubMed Web of Science ®Google Scholar
• Pectasides D, Pectasides M, Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Eur. Urol. 48, 60–68 (2005).
   PubMedGoogle Scholar
• von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter Phase III study. J. Clin. Oncol. 17, 3068–3077 (2000).
   Google Scholar
• Hussain SA, Stocken DD, Riley P et al. A Phase I/II study of gemcitabine and fractionated cisplatin in an out-patient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br. J. Cancer. 91, 844–849 (2004).
   PubMed Web of Science ®Google Scholar
• Bamias A, Aravantinos G, Deliveliotis C et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, Phase III study from the Hellenic Co-operative Oncology Group. J. Clin. Oncol. 22, 220–228 (2004).
   PubMed Web of Science ®Google Scholar
• Linardou H, Aravantinos G, Efstathiou E et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology 64, 479–484 (2004).
   PubMed Web of Science ®Google Scholar
• Turkolmez K, Beduk Y, Baltaci S et al. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. Eur. Urol. 44, 682–686 (2003).
   PubMedGoogle Scholar
• Thalmann GN, Markwalder R, Shahin O et al. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J. Urol. 172, 70–75 (2004).
   PubMed Web of Science ®Google Scholar
• Serretta V, Pavone C, Ingargiola GB et al. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression, and survival in 137 selected patients followed up to 20 years. Eur. Urol. 45, 730–736 (2004).
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Cheng L. Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls, and prognostic significance. Pathology 35, 484–491 (2003).
   PubMed Web of Science ®Google Scholar
• Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transistional cell carcinoma of the bladder. J. Urol. 167, 1573–1583 (2002).
   PubMed Web of Science ®Google Scholar
• del Muro XG, Condom E, Vigues F et al. p53 and p21 expression levels predict organ preservation and survival in invasive bladder cancer treated with a combined-modality approach. Cancer 100, 1859–1867 (2004).
   PubMedGoogle Scholar
• Kragelj B, Zaletel-Kragelj L, Sedmak, B et al. Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Rad. Onc. 75, 44–47 (2005).
   PubMed Web of Science ®Google Scholar
• Pavy JJ, Denekamp J, Letschert J et al. Late effects toxicity scoring: the SOMA scale. Int. J. Radiat. Oncol. Biol. Phys. 31, 1043–1047 (1995).
   PubMed Web of Science ®Google Scholar
• Michaelson MD, Shipley WU, Heney NM et al. Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. Br. J. Cancer 90, 578–581 (2004).
   PubMedGoogle Scholar
• Lodde M, Palermo S, Comploj E et al. Four years experience in bladder preserving management for muscle invasive bladder cancer. Eur. Urol. 47, 773–779 (2005).
   PubMed Web of Science ®Google Scholar
• Shelley MD, Wilt TJ, Barber J et al. A meta-analysis of randomized trials suggests a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: are these data relevant to modern practice? Clin. Oncol. 16, 166–171 (2004).
   Web of Science ®Google Scholar
• Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 60, 822–824 (2002).
   PubMed Web of Science ®Google Scholar
• Grimm M, Steinhoff C, Simon X et al. Effect of routine repeat transurethral resection of superficial bladder cancer: a long-term observational study. J. Urol. 170, 433–477 (2003).
   PubMed Web of Science ®Google Scholar
• Jakse G, Algaba F, Malmstrom P, Oosterlinck W. A second-look TUR in T1 transistional cell carcinoma: why? Eur. Urol. 45, 539–546 (2004).
   PubMed Web of Science ®Google Scholar
• Luo Y, Chen X, Downs TM et al. IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis Bacillus Calmette-Guerin immunotherapy. J. Immunol. 162, 2399–2405 (1999).
   PubMed Web of Science ®Google Scholar
• O’Donnell MA, Krohn J, Dewolf WC. Salvage intravesical therapy with interferon-α-2b plus low dose Bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom Bacillus Calmette-Guerin alone previously failed. J. Urol. 166, 1300–1304 (2001).
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Kiemeney LA, Gofrit ON et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transistional cell carcinoma of the bladder. Eur. Urol. 46, 65–72 (2004).
   PubMed Web of Science ®Google Scholar
• Columbo R, Da Pozzo LF, Salonia A et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transistional cell carcinoma. J. Clin. Oncol. 21, 4270–4276 (2003).
   PubMedGoogle Scholar
• Di Stasi SM, Giannantoni A, Stephen RL et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high-risk superficial bladder cancer: a prospective randomized study. J. Urol. 170, 777–782 (2003).
   PubMed Web of Science ®Google Scholar
• Herr HW. Surgical factors in the treatment of superficial and invasive bladder cancer. Urol. Clin. N. Am. 32, 157–164 (2005).
   PubMedGoogle Scholar
• Simonato A, Gregori A, Lissiani A et al. Laparoscopic radical cystoprostatectomy: our experience in a consecutive series of 10 patients with a 3 years follow-up. Eur. Urol. 47, 785–792 (2005).
   PubMed Web of Science ®Google Scholar
• Cathelineau X, Arroyo C, Rozet F et al. Laparoscopic assisted radical cystectomy: the Montsouris experience after 84 cases. Eur. Urol. 47, 780–784 (2005).
   PubMed Web of Science ®Google Scholar